Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,029Revenue $M37.0Net Margin (%)-163.7Z-Score-3.6
Enterprise Value $M934EPS $-0.3Operating Margin %-284.8F-Score1
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-163.7Higher ROA y-yN
Price/Book19.410-y EBITDA Growth Rate %-29.4Quick Ratio2.5Cash flow > EarningsN
Price/Sales25.15-y EBITDA Growth Rate %-45.7Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-18.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-68.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M241ROI % (ttm)-11.9Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 4.49-16%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 4.4962%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 4.4965%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.490view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-10.2view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-28.27view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-18.21view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-23.25view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-23.25view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-36.31view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-35.86view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-28.84view
Nova Tina SusanDirector 2014-04-14Sell35,000$6.22-27.81view

Press Releases about ARNA :

    Quarterly/Annual Reports about ARNA:

    News about ARNA:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
    WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
    comment on ARNA Mar 15 2013 
    comment on ARNA Mar 02 2013 
    WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 


    More From Other Websites
    Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog Apr 23 2015
    Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of... Apr 23 2015
    Zacks Rank #5 Additions for Tuesday - Tale of the Tape Apr 21 2015
    Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
    ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 10 2015
    Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of... Apr 10 2015
    Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen Apr 10 2015
    Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference Apr 09 2015
    Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference Apr 09 2015
    Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog Apr 08 2015
    Calls look to ride Arena Pharma Apr 08 2015
    Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval Apr 07 2015
    Arena Pharmaceuticals shares rise on weight loss drug patent Apr 07 2015
    Arena Pharmaceuticals shares rise on weight loss drug patent Apr 07 2015
    Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States... Apr 07 2015
    Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States... Apr 07 2015
    3 Ways Arena Can Boost Shareholder Value Apr 02 2015
    Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? Apr 02 2015
    Sports & Entertainment Group Announces Strategic Partnership with AEG Facilities for Québec City... Apr 02 2015
    Zacks Rank #5 Additions for Thursday - Tale of the Tape Mar 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK